chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Principles of Therapy

  • In general, the choice of first-line therapy may depend on risk score, physician's experience, age, ability to tolerate therapy & comorbid conditions

Targeted Cancer Therapy

Adherence to tyrosine kinase inhibitors (TKI) therapy

  • Predicts the achievement of complete molecular response (CMR) on standard-dose Imatinib
  • The marker that identifies a non-adherent CP-CML patient is the BCR-ABL1 doubling time
  • Educate the patient on their adherence to tyrosine kinase inhibitor therapy & monitor them closely
  • Non-adherence may result to poorer treatment response that can result to loss of major molecular response, hematologic failure, cytogenic relapse & treatment failure
  • Appropriate management of the side effects will improve patient adherence

Discontinuation of tyrosine kinase inhibitors (TKI) therapy

  • Should only be considered in patients who are eligible for clinical trial
  • In patients with responsive disease, continuation of tyrosine kinase inhibitors therapy is recommended

Pharmacotherapy

First-generation tyrosine kinase inhibitors (TKI)

Imatinib

  • Belongs to a class of signal transduction inhibitors (STIs) that interferes with the intracellular signaling pathways associated with malignancies
  • Inhibits the BCR-ABL tyrosine protein kinase in all phases of chronic myeloid leukemia
  • Recommended as 1st-line treatment for patients with chronic phase & advanced phase chronic myeloid leukemia
  • Several studies showed cytogenic response, hematologic response, decreased relapse & disease progression, & high overall survival in patients given Imatinib therapy

Second-generation tyrosine kinase inhibitors (TKI)

Bosutinib

  • An oral multi-TKI that is used to treat adult patients with chronic phase, accelerated phase or blast phase Ph-positive (Ph+) chronic myeloid leukemia with resistance or intolerance to previous therapy (eg Imatinib, Dasatinib & Nilotinib)
  • Inhibits BCR-ABL1 kinase that promotes chronic myeloid leukemia & Src-family of kinases (eg Src, Lyn & Hck)
  • More potent for the BCR-ABL1 kinase than Imatinib
  • Not an efficient substrate for multidrug resistant transporters
  • Used for the management of cytogenetic or hematologic resistance to tyrosine kinase inhibitors & in patients with E255K/V, F317L/V/I/C, F359V/C/I, T315A, or Y253H mutations
  • At present, Bosutinib is not recommended as 1st-line therapy for patients newly diagnosed with chronic phase chronic myeloid leukemia

Dasatinib

  • An oral multi-TKI & is more potent in the inhibition of ABL than Imatinib
  • Inhibits Src tyrosine kinase, BCR-ABL & Imatinib-resistant mutations of BCR-ABL & binds to both active & inactive conformation of the ABL kinase domain
  • Recommended for all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy of Imatinib, Ph+ ALL with resistance or intolerance to prior therapy & in newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase
  • Preferred 1st-line treatment for patients with chronic phase chronic myeloid leukemia with intermediate- to high-risk score
    • Also preferred in patients with history of arrhythmia, heart disease, pancreatitis & hyperglycemia
  • Used for the management of cytogenetic or hematologic resistance to tyrosine kinase inhibitors & in patients with Y253H, E255K/V or F359V/C/I mutations

Nilotinib

  • Used for adult patients who are newly diagnosed with Ph+ chronic phase chronic myeloid leukemia
  • Also used to treat chronic & accelerated Ph+ chronic myeloid leukemia patients who are intolerant or resistant to a prior therapy that includes Imatinib
  • Preferred 1st-line treatment for patients with chronic phase chronic myeloid leukemia with intermediate- to high-risk score
  • Selectively inhibits the BCR-ABL1 tyrosine kinase & enhances the binding site affinity which makes Nilotinib 30 times more potent than Imatinib in Imatinib-sensitive chronic myeloid leukemia cell lines & 3-7 times more potent in Imatinib-resistant chronic myeloid leukemia cell lines
  • Used for the management of cytogenetic or hematologic resistance to tyrosine kinase inhibitors & in patients with F317L/V/I/C, T315A or V299L mutations

Ponatinib

  • An oral multi-kinase inhibitor that inhibits the ABL & T315l mutant ABL genes
  • Used for the treatment of T3151l-positive CP-, AP-, or BP-CML or T315l-positive Ph+ALL & in patients with CP-, AP-, or BP-CML or Ph+ALL for patients when no other tyrosine kinase inhibitor is indicated

Management of Tyrosine kinase inhibitors Therapy Toxicities

Imatinib

  • Chronic phase chronic myeloid leukemia with ANC <1.0 x 109/L &/or platelet count <50 x 109/L
    • Withhold therapy until ANC ≥1.5 x 109/L &/or platelet count ≥75 x 109/L, then resume at 400 mg initial dose, or 300 mg initial dose for recurrence
  • Accelerated & blast phase chronic myeloid leukemia with ANC <0.5 x 109/L &/or platelet count <10 x 109/L
    • Reduce dose to 400 mg if patient develops cytopenia unrelated to chronic myeloid leukemia
    • Reduce dose further to 300 mg if with persistent neutropenia after 2 weeks
    • Withhold Imatinib is still with cytopenia after 4 weeks, then resume at 300 mg dose if ANC ≥1.0 x 109/L & platelet count ≥20 x 109/L
  • Combination with growth factors may be considered for resistant neutropenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia
  • Withhold therapy if patient has bilirubin >3 x institutional ULN (IULN) or liver transaminases >5 x IULN
    • Resume therapy when bilirubin level is reduced to <1.5 x ULN & liver transaminases to <2.5 x IULN
  • Interrupt administration if any the following are present: severe hepatotoxicity, severe fluid retention, rashes

Bosutinib

  • ANC <1.0 x 109/L or platelet count <50 x 109/L
    • Withhold treatment until ANC reaches ≥1.0 x 109/L & platelet count ≥50 x 109/L
    • May resume Bosutinib treatment when blood count returns to normal within 2 weeks
    • Reduce dose to 100 mg if blood counts remain low after 2 weeks; further dose reduction to 100 mg more may be considered for recurrence of cytopenia
  • Combination with growth factors may be considered for resistant neutropenia & thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia
  • Withhold therapy if patient's liver transaminases >5 x IULN
    • Resume therapy at 400 mg daily when liver transaminases are reduced to ≤2.5 x IULN
    • Discontinue Bosutinib if recovery takes longer than 4 weeks, or if with transaminase elevations >3 x IULN, bilirubin >2 x IULN, & alkaline phosphatase <2 x ULN
  • Withhold therapy if with grade 3-4 diarrhea, rashes, & other clinically significant, moderate, or severe non-hematologic toxicities until symptoms resolve
    • May resume treatment at 400 mg once daily when toxicity has resolved (ie diarrhea resolves to grade ≤1)

Dasatinib

  • Chronic phase chronic myeloid leukemia with ANC <0.5 x 109/L or platelet count <50 x 109/L
    • Withhold therapy until ANC ≥1.0 x 109/L & platelet count ≥50 x 109/L, if platelet count is <25 x 109/L, or for recurrence of ANC <0.5 x 109/L for 7 days
    • May resume treatment if blood count returns to normal after ≤7 days or at a reduced dose of 80 mg once daily for recurrence; reduce dose further to 50 mg once daily or discontinue treatment if at 3rd recurrence
  • Accelerated & blast phase chronic myeloid leukemia with ANC <0.5 x 109/L &/or platelet count <10 x 109/L
    • Withhold treatment if patient develops cytopenia unrelated to chronic myeloid leukemia, then resume at initial dose if with ANC ≥1.0 x 109/L & platelet count ≥20 x 109/L, or at a reduced dose of 100 mg/day if for recurrence, or at 80 mg once daily for 3rd recurrence 
  • Combination with growth factors may be considered for resistant neutropenia & thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia
  • Dasatinib should be discontinued permanently for confirmed presence of pulmonary arterial hypertension
  • Withhold therapy if with rashes & severe non-hematologic toxicities until symptoms resolve
    • May resume treatment at reduced dose depending on severity of adverse effect

Nilotinib

  • Monitor serum potassium & magnesium levels, ECG, glucose levels
  • Withhold treatment for any of the following:
    • ECG with QTc >480 msec
      • May resume treatment within 2 weeks at prior dose if with QTcF <450 msec & within 20 msec of baseline
      • May resume at reduced dose if QTcF between 450-480 msec after 2 weeks
      • Discontinue Nilotinib if QTcF returns to >480 msec after dose reduction
    • Chronic or accelerated phase, ANC <1.0 x 109/L &/or platelet count <50 x 109/L
    • Elevated serum lipase, amylase, bilirubin, or hepatic transaminases grade ≥3
  • Discontinue Nilotinib if with confirmed peripheral arterial occlusive disease
  • Combination with growth factors may be considered for resistant neutropenia & thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia

Ponatinib

  • Withhold treatment for any of the following:
    • ANC <1.0 x 109/L &/or platelet count <50 x 109/L
      • May resume therapy at initial dose (45 mg), at 30 mg if at 2nd occurrence, & at 15 mg if at 3rd occurrence when results are ANC ≥1.5 x 109/L & platelet count ≥75 x 109/L
    • Elevated serum lipase (symptomatic grade 1/2), amylase, bilirubin, or hepatic transaminases grade >3 x IULN (grade ≥2)
      • May resume treatment at reduced dose in patients with liver transaminase <3 x IULN, serum lipase <1.5 x ULN or ≤grade 1
    • Symptomatic grade 3 pancreatitis
      • Consider treatment resumption when serum lipase levels return to ≤grade 1 at a lower dose
    • Cerebral or GI hemorrhage, rashes, or fluid retention
  • Discontinue Ponatinib if patients receiving 15 mg doses present with liver transaminase of >3 x IULN, grade 4 symptomatic pancreatitis, & in patients with AST/ALT ≥3 x ULN plus bilirubin >2 x ULN & alkaline phosphatase <2 x ULN
  • Monitor for thromboembolism, cardiac function, & hepatic function
  • Combination with growth factors may be considered for resistant neutropenia & thrombocytopenia
  • Transfusion support may be considered in patients with symptomatic grade 3-4 anemia

Antineoplastic agent

Omacetaxine mepesuccinate

  • A cephalotaxine ester that inhibits protein synthesis by binding to the A-site located at the peptidyl-transferase center of the large ribosomal subunit & reduces the protein levels of BCR-ABL & myeloid leukemia cell 1 (MCL-1) that is independent of the direct BCR-ABL binding
  • Used to treat patients who have chronic phase chronic myeloid leukemia or accelerated phase chronic myeloid leukemia with disease progression that is resistant or intolerant to 2 or more tyrosine kinase inhibitors
  • Reported adverse effects with Omacetaxine therapy include grade 3 or 4 hyperglycemia & CBC abnormalities
    • Delay treatment if patient presents with ANC <0.5 x 109/L or platelet count <50 x 109/L
    • May resume at reduced dose every 2 days for the next cycle if with ANC ≥1.0 x 109/L & platelet count ≥50 x 109/L

Cytotoxic chemotherapy

Hydroxyurea

  • An antimetabolite that rapidly reduces high white blood cell counts
  • Inhibits the ribonucleotide reductase & DNA synthesis & does not interfere with protein or RNA synthesis
  • Treatment option for symptomatic leukocytosis or thrombocytosis

Clinical trials

  • Considerations for enrollment in clinical trials
    • In patients with accelerated phase chronic myeloid leukemia or blast phase chronic myeloid leukemia
    • In patients with treatment failure after Imatinib therapy
    • For patients with BCR-ABL1 transcripts >10% (IS) after initial treatment with 2nd-line tyrosine kinase inhibitors at 3-months evaluation
    • For patients with BCR-ABL1 transcripts >10% (IS) or lack of PCyR on bone marrow cytogenetics after initial treatment with 2nd-line tyrosine kinase inhibitors at 6-months evaluation
    • For patients with cytogenic relapse, or less than PCyR or BCR-ABL1 transcripts >10% (IS) at 12-months evaluation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017